MIRA), a preclinical-stage pharmaceutical company, proudly announces the successful completion of its current Good Laboratory Practice (GLP) preclinical safety program for Ketamir-2, a novel oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results